Company intelligence / Profile preview

Rapigen

Suwon-si, Gyeonggi-do, SOUTH KOREArapigen.com ↗

Ownership: Private
Development stage: Other

Overview

Rapigen has developed and commercialized a broad portfolio of rapid diagnostic kits for veterinary and human infectious diseases as well as food safety. The company holds multiple regulatory approvals including ISO9001/13485 certification and Korea FDA clearances for several products. Its products are exported globally. Clinical results are not directly reported but the company’s long-standing market presence suggests established performance.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic kit (in-vitro diagnostic)PCR kit (Polymerase chain reaction-based diagnostics)Immunodiagnostic product (Antibody-based rapid test kits)Veterinary diagnostic kitSmall molecule detection assay (for food/environmental safety)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Rapigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapigen.

Explore the full profile